14 November 2024 - The objective was to describe the type of evidence and the clinical benefit of cancer medicines assessed for funding in Australia by the PBAC and to assess it with the European Society of Medical Oncology Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS).

All data on applications submitted to PBAC between 2010 and 2020 were extracted from PBAC Public Summary Documents available online. ESMO-MCBS ratings were retrieved from the ESMO-MCBS website.

Read International Journal of Technology Assessment in Health Care article